Literature DB >> 12839838

Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease.

Federica Sotgia1, Scott E Woodman, Gloria Bonuccelli, Franco Capozza, Carlo Minetti, Philipp E Scherer, Michael P Lisanti.   

Abstract

Four different phenotypes have been associated with CAV3 mutations: limb girdle muscular dystrophy-1C (LGMD-1C), rippling muscle disease (RMD), and distal myopathy (DM), as well as idiopathic and familial hyperCKemia (HCK). Detailed molecular characterization of two caveolin-3 mutations (P104L and DeltaTFT), associated with LGMD-1C, shows them to impart a dominant-negative effect on wild-type caveolin-3, rendering it dysfunctional through sequestration in the Golgi complex. Interestingly, substitution of glutamine for arginine at amino acid position 26 (R26Q) of caveolin-3 is associated not only with RMD but also with DM and HCK. However, the phenotypic behavior of the caveolin-3 R26Q mutation has never been evaluated in cultured cells. Thus we characterized the cellular and molecular properties of the R26Q mutant protein to better understand how this mutation can manifest as such distinct disease phenotypes. Here, we show that the caveolin-3 R26Q mutant is mostly retained at the level of the Golgi complex. The caveolin-3 R26Q mutant formed oligomers of a much larger size than wild-type caveolin-3 and was excluded from caveolae-enriched membranes. However, caveolin-3 R26Q did not behave in a dominant-negative fashion when coexpressed with wild-type caveolin-3. Thus the R26Q mutation behaves differently from other caveolin-3 mutations (P104L and DeltaTFT) that have been previously characterized. These data provide a possible explanation for the scope of the various disease phenotypes associated with the caveolin-3 R26Q mutation. We propose a haploinsufficiency model in which reduced levels of wild-type caveolin-3, although not rendered dysfunctional due to the caveolin-3 R26Q mutant protein, are insufficient for normal muscle cell function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839838     DOI: 10.1152/ajpcell.00166.2003

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  17 in total

1.  Differential effects of myopathy-associated caveolin-3 mutants on growth factor signaling.

Authors:  Eva Brauers; Agnes Dreier; Andreas Roos; Berthold Wormland; Joachim Weis; Alexander Krüttgen
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

Review 2.  Caveolins and cavins in the trafficking, maturation, and degradation of caveolae: implications for cell physiology.

Authors:  Anna R Busija; Hemal H Patel; Paul A Insel
Journal:  Am J Physiol Cell Physiol       Date:  2017-01-25       Impact factor: 4.249

Review 3.  Emerging Insights into the Molecular Architecture of Caveolin-1.

Authors:  Melanie D Ohi; Anne K Kenworthy
Journal:  J Membr Biol       Date:  2022-08-16       Impact factor: 2.426

4.  Caveolin-3 associates with and affects the function of hyperpolarization-activated cyclic nucleotide-gated channel 4.

Authors:  Bin Ye; Ravi C Balijepalli; Jason D Foell; Stacie Kroboth; Qi Ye; Yu-Hong Luo; Nian-Qing Shi
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

Review 5.  Distal myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-05-15       Impact factor: 3.806

Review 6.  From embryonic development to human diseases: The functional role of caveolae/caveolin.

Authors:  Jihee Sohn; Rachel M Brick; Rocky S Tuan
Journal:  Birth Defects Res C Embryo Today       Date:  2016-03-17

7.  Overexpression of caveolin-1 is sufficient to phenocopy the behavior of a disease-associated mutant.

Authors:  Caroline A Hanson; Kimberly R Drake; Michelle A Baird; Bing Han; Lewis J Kraft; Michael W Davidson; Anne K Kenworthy
Journal:  Traffic       Date:  2013-04-07       Impact factor: 6.215

Review 8.  RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.

Authors:  Jian Liu; Scott Q Harper
Journal:  Curr Gene Ther       Date:  2012-08       Impact factor: 4.391

9.  Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases.

Authors:  Federica Sotgia; Gloria Bonuccelli; Carlo Minetti; Scott E Woodman; Franco Capozza; Robert G Kemp; Philipp E Scherer; Michael P Lisanti
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

10.  Palmitate diet-induced loss of cardiac caveolin-3: a novel mechanism for lipid-induced contractile dysfunction.

Authors:  Catherine J Knowles; Martina Cebova; Ilka M Pinz
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.